• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Dominari Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    6/26/26 4:30:26 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOMH alert in real time by email
    false 0000012239 0000012239 2026-06-24 2026-06-24 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

     

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 24, 2026

     

     

     

    Dominari Holdings Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-41845   52-0849320
    (State or Other Jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    725 5th Avenue, 22nd Floor

    New York, NY 10022

    (Address of Principal Executive Offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (212) 393-4540

     

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, $0.0001 par value   DOMH   The Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 4.01. Changes in Registrant’s Certifying Accountant

     

    (a) Dismissal of Previous Independent Registered Public Accounting Firm

     

    On June 24, 2026, Dominari Holdings Inc. (the “Company”), with the approval of the audit committee of the board of directors of the Company (the “Audit Committee”), dismissed CBIZ CPAs P.C. (“CBIZ CPAs”) as the Company’s independent registered public accounting firm.

     

    As previously disclosed in a Current Report on Form 8-K filed on April 30, 2025, on April 25, 2025, Marcum LLP was dismissed, and CBIZ CPAs was appointed as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2025.

     

    For the period from April 25, 2025 through the date of CBIZ CPAs’ dismissal, the report of CBIZ CPAs on the financial statements did not contain an adverse opinion or a disclaimer of opinion, or was qualified or modified as to uncertainty, audit scope, or accounting principles. There were no disagreements, as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions thereto, between the Company and CBIZ CPAs on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of CBIZ CPAs, would have caused CBIZ CPAs to make reference to the subject matter of the disagreements in connection with its audit reports on the Company’s financial statements.

     

    For the period from April 25, 2025 through the date of CBIZ CPAs’ dismissal, there were no “reportable events” within the meaning of Item 304(a)(1)(v) of Regulation S-K except for the following material weaknesses in our internal control over financial reporting related to: (i) the lack of personnel to ensure the books and records are closed accurately and on a timely basis, (ii) lack of sufficient review over the accounting for certain transactions recorded at fair value, (iii) the lack of appropriate segregation of duties, (iv) certain general information technology control deficiencies regarding user access provisioning and administrative access review, and (v) insufficient documentation to support and evidence the design and implementation of controls.

     

    The Company provided CBIZ CPAs with a copy of this Current Report on Form 8-K prior to its filing with the Securities and Exchange Commission (“SEC”) and requested that CBIZ CPAs furnish the Company with a letter addressed to the SEC stating whether it agrees with the above statements and, if it does not agree, the respects in which it does not agree. A copy of the letter furnished by CBIZ CPAs, dated June 26, 2026, is filed as Exhibit 16.1 to this Current Report on Form 8-K.

     

    (b) Appointment of New Independent Registered Public Accounting Firm

     

    On June 24, 2026, the Company engaged Grassi & Co., CPAs, P.C. (“Grassi”) to serve as its independent registered public accounting firm for the fiscal year ending December 31, 2026.

     

    During the Company’s fiscal years ended December 31, 2025 and 2024, and during the interim period from the end of the most recently completed fiscal year through June 24, 2026, the date of engagement of Grassi, neither the Company nor anyone on behalf of the Company consulted with Grassi regarding (a) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s financial statements as to which the Company received a written report or oral advice that Grassi concluded was an important factor considered by the Company in reaching a decision on any accounting, auditing or financial reporting issue; or (b) any matter that was the subject of a disagreement or a reportable event as defined in Items 304(a)(1)(iv), and the related instructions thereto, and (v), respectively, of Regulation S-K.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    16.1   Letter from CBIZ CPAs P.C. to the U.S. Securities and Exchange Commission, dated June 26, 2026.
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      DOMINARI HOLDINGS INC.
         
    Date: June 26, 2026 By: /s/ Anthony Hayes
        Anthony Hayes
        Chief Executive Officer

     

    2

     

    Get the next $DOMH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOMH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DOMH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Ledwick Tim S

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/25/26 8:10:56 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Hayes Anthony

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:32 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haug Kyle

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    3/24/26 9:23:14 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: CEO Hayes Anthony bought $89,054 worth of shares (23,000 units at $3.87), increasing direct ownership by 1% to 1,750,873 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:22:01 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: President Wool Kyle Michael bought $96,798 worth of shares (25,000 units at $3.87), increasing direct ownership by 2% to 1,211,828 units (SEC Form 4)

    4/A - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 9:20:35 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Wool Kyle Michael decreased direct ownership by 1% to 2,453,817 units (SEC Form 4)

    4 - Dominari Holdings Inc. (0000012239) (Issuer)

    12/10/25 7:54:17 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    SEC Filings

    View All

    Dominari Holdings Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    6/26/26 4:30:26 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - Dominari Holdings Inc. (0000012239) (Filer)

    5/27/26 5:00:42 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Dominari Holdings Inc.

    10-Q - Dominari Holdings Inc. (0000012239) (Filer)

    5/12/26 9:42:51 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dominari Securities Raises $200,000,000.00 in World's Largest IPO

    ~ Dominari Allocated 1,481,481 IPO shares of SpaceX NEW YORK, June 15, 2026 /PRNewswire/ -- Dominari Securities LLC, a wholly owned subsidiary of Dominari Holdings Inc. (NASDAQ:DOMH), is pleased to announce the successful launch and closing of the American Ventures Opportunity QP Series IV – SpaceX Fund, (hereinafter, the "Fund"). The Fund successfully raised approximately $200,000,000.00 from qualified investors and deployed that capital to directly acquire 1,481,481 IPO shares of SpaceX at a price of $135.00 per share in what the Wall Street Journal called the smoothest IPO in recent history, as well as the largest IPO ever.

    6/15/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    The Rise of the American Drone Industry

    NEW YORK, June 2, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today issued the following letter to shareholders: Dear Shareholder,The rise of drones in our society has become ubiquitous. Whether it's the discussion of their use to make deliveries, their use to cover sporting events, or their constant presence when discussing conflicts in the middle east, drones are everywhere. And at Dominari, we are proud to play our part in building and supporting this growing American industry.Since our inception, Dominari has been involved in supporting this important new facet

    6/2/26 8:00:00 AM ET
    $DOMH
    $JFB
    $UMAC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    General Bldg Contractors - Nonresidential Bldgs
    Consumer Discretionary

    Dominari Holdings Congratulates Cerebras Systems on "Blockbuster" Initial Public Offering

    Shares Skyrocket in Debut as AI Mania Grips Wall Street According to ReutersNEW YORK, May 15, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") congratulates Cerebras Systems (NASDAQ:CBRS), on its Initital Public Offering, which has been called a "Blockbuster Debut" as the next hot AI stock, by Investor's Business Daily. On May 14, 2026, Cerebras stock opened at $185.00 and closed $126 higher at $311.07 per share, an approximate 68% increase on its first day of trading. Dominari Securities' SPV 1 & 2 invested early in Cerebras, at $39.00 per

    5/15/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Leadership Updates

    Live Leadership Updates

    View All

    Dominari Expands Strategic Leadership with Appointment of Ambassador Jamie McCourt to Advisory Board

    Dominari Withdraws $2 Billion Shelf Registration NEW YORK, Dec. 8, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) today announced a major enhancement to its strategic leadership with the appointment of Ambassador Jamie McCourt to the Advisory Board of Dominari Securities. Separately, the company has formally withdrawn its previously filed $2 billion shelf registration statement, reflecting confidence in its financial position and growth outlook. Globally recognized diplomat, executive and entrepreneur Ambassador Jamie McCourt Joins Advisory Board Ambassador McCourt

    12/8/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Receives Approval as a Limited Underwriting Member of the New York Stock Exchange

    Enables direct participation in underwriting activities conducted through NYSE and NYSEAmerican platforms NEW YORK, Oct. 9, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today announced that its wholly owned subsidiary, Dominari Securities LLC, has been approved as a Limited Underwriting member of the New York Stock Exchange and NYSE American Equities (the "Exchanges") effective October 8, 2025. This approval marks an important regulatory milestone for Dominari Securities as it continues to expand its capabilities within U.S. capital m

    10/9/25 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Securities Appoints Communications and Growth Strategist Brian Parsley to Board

    Accomplished entrepreneur and global speaker to strengthen firm's marketing, investor engagement and strategic communications to help drive growth NEW YORK, Sept. 10, 2025 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH), today announced the appointment of Brian Parsley to its Board of Directors. Parsley, an accomplished entrepreneur, behavioral analyst and internationally recognized speaker, will support the firm's growth by enhancing its marketing, investor outreach and overall communications strategy. Mr. Parsley has more than 30 years of experience in entrepreneurship,

    9/10/25 8:30:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Financials

    Live finance-specific insights

    View All

    Dominari Holdings Issues Shareholder Letter

    Company Reports Revenue of $35.8 million up 395% from prior yearTotal Capital invested across all SPV Series: approximately $292 millionRecord Date of May 15th for $9 Million Dividend PaymentNEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company") today issued the following letter to shareholders: Dear Shareholder,As we approach mid-year, I want to take this opportunity to thank you for being a Dominari shareholder and provide you with some updates.10Q SummaryThe year is off to a strong start. As noted in our 10Q just filed with t

    5/13/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Q1 Revenue Increases by 395% Over Q1 2025

    Underwriting revenues increased over five-fold NEW YORK, May 13, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) ("Dominari" or the "Company"), today announced highlights of its financial results for the quarter ended March 31, 2026, which were filed with the Securities and Exchange Commission ("SEC") in the Company's quarterly SEC Form 10Q. The Company stated that:  "In  the first quarter of 2026,  we experienced continued revenue growth mainly from underwriting services, increased our annual recurring revenue from our management fees that we earn on deals that we bri

    5/13/26 7:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dominari Holdings Announces Record Date for Cash Dividend

    NEW YORK, May 4, 2026 /PRNewswire/ -- Dominari Holdings Inc. (NASDAQ:DOMH) is pleased to announce that its board of directors has authorized a special cash dividend of, in the aggregate, approximately $9 million, or approximately $0.31 per share. The dividend is payable on or about May 29, 2026, to DOMH's common stock shareholders and certain DOMH warrant holders (on an as-exercised basis) of record as of the close of business on May 15, 2025. For additional information about Dominari Holdings Inc., please visit: https://www.dominariholdings.com/About Dominari Holdings Inc.The C

    5/4/26 8:00:00 AM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOMH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 8:56:04 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Dominari Holdings Inc.

    SC 13D/A - Dominari Holdings Inc. (0000012239) (Subject)

    6/13/24 4:32:07 PM ET
    $DOMH
    Biotechnology: Pharmaceutical Preparations
    Health Care